Esophageal cancer (EC) is a highly lethal malignancy, and the incidence is increasing[@b1]. In 2015, it has been estimated that there would be 16,980 new EC cases and 15,590 deaths in the United States[@b2]. Approximately 50% of patients had metastases to distant lymph nodes or organs at the initial diagnosis[@b3][@b4]. The prognosis of metastatic EC is poor, and the 5-year survival rate is lower than 5%[@b5]. The palliative treatment in metastatic EC depends mainly on patients' clinical situation with the goal of reducing cancer-related symptoms and extending survival without compromising quality of life. Systemic treatment consists of chemotherapy, targeted therapy, and best supportive care. Local treatment mainly includes feeding tubes, beam radiation, brachytherapy, and endoscopic management techniques such as dilation and stenting[@b6][@b7].

Preoperative chemoradiotherapy may significantly increase the radical resection rate and improve survival for advanced esophageal carcinoma[@b8], but the value of surgery plus radiotherapy (RT) for metastatic EC has not yet been clarified. RT is not a first-line treatment for metastatic EC, but RT may improve the patients' symptoms of obstruction[@b9]. Studies with small sample sizes have shown that local treatments including surgery could prolong survival in metastatic EC[@b10][@b11][@b12][@b13]. Studies have shown that surgery and/or radiotherapy can improve survival in patients with stage IV malignant tumors[@b14][@b15]. In this study, we analyzed the metastatic EC using a population-based national registry (Surveillance Epidemiology and End Results, SEER) to determine the impact of local treatment strategies on survival in metastatic EC.

Results
=======

Patient characteristics and treatment
-------------------------------------

The SEER database included a total of 63,759 patients with EC in 1988--2012, and 31.6% (20,168 patients) had a distant stage; 9,125 patients met the inclusion criteria of this study ([Fig. 1](#f1){ref-type="fig"}). The patient characteristics are shown in [Table 1](#t1){ref-type="table"}. The median age of initial diagnosis was 64 years (range, 21--96); 83.5% (7,621/9,125) were white; 82.0% (7,486/9,125) were male; 59.2% (5,406/9,125) had adenocarcinoma; and 76.7% (6,995/9,125) had a lower thoracic esophageal cancer. Local treatment modalities were as follows: 426 (4.7%) patients underwent primary cancer-directed surgery (CDS); 4,786 (52.4%) were primary RT alone; 847 (9.3%) underwent CDS plus RT; and 3,066 (33.6%) were not administered any local treatment. Among patients who underwent CDS plus RT, 57.3% (485/847) were administered preoperative radiotherapy, while 38.3% (324/847) were received postoperative radiotherapy and 4.5% (38/847) were underwent both preoperative and postoperative RT.

Survival
--------

The median follow-up time for all patients was 9 months (range, 4--261 months) with a median survival time was 10 months. The 1 year, 2 years, 3 years, 5 years, and 10 years OS rates were 40.5%, 14.6%, 8.4%, 5.4%, and 3.5%, respectively ([Fig. 2](#f2){ref-type="fig"}).

Prognostic factors analysis
---------------------------

Univariate analysis showed that year of diagnosis, age, race, tumor histology, grade, and local treatment modalities were risk factors for OS ([Table 2](#t2){ref-type="table"}).

Multivariate analysis indicated that year of diagnosis, age at diagnosis, race, tumor histology, grade, and local treatment modalities were independent prognostic factors for OS. Patients who underwent primary CDS was significantly better OS than that of patients who were primary RT alone (HR, 1.440; 95% CI, 1.287--1.611; *P* \< 0.001) and who were not received any local treatment (HR, 1.602; 95% CI, 1.427--1.799; *P* \< 0.001). Surgery combined with RT could further improve survival (HR, 0.793; 95% CI, 0.693--0.908; *P* = 0.001) ([Table 3](#t3){ref-type="table"}).

Survival after local treatment
------------------------------

The 5-year OS rates were 8.4%, 4.5%, 17.5%, and 3.4% for primary CDS, RT alone, CDS plus RT, and no local treatment, respectively, with a median survival time of 11.0, 9.0, 15.0, and 9.0 months, respectively (*P* \< 0.001) ([Fig. 3](#f3){ref-type="fig"}). Patients who were received preoperative RT was significantly better OS than that of patients who underwent primary CDS and CDS plus postoperative RT, with 5-year OS rates of 24.7%, 6.5%, and 7.8%, respectively, and a median survival time of 20.0, 11.0, and 12.0 months, respectively (*P* \< 0.001) ([Fig. 4](#f4){ref-type="fig"}).

We determined the effect of local treatment modalities on OS by year of diagnosis. It was significantly associated with OS from 1988 to 1999 (log-rank test *P* \< 0.001) ([Figure S1A](#S1){ref-type="supplementary-material"}) and from 2000 to 2012 (*P* \< 0.001) ([Figure S1B](#S1){ref-type="supplementary-material"}). However, the survival benefit was significantly better from 2000 to 2012 for those treated with CDS plus RT.

The prognostic effect of local treatment modalities was examined based on different ethnicities. In black patients, CDS with or without RT improved OS than that of patients who underwent primary RT alone or did not have any local treatment (*P* \< 0.001) ([Figure S2A](#S1){ref-type="supplementary-material"}). In white patients, OS was better for patients who underwent CDS plus RT, as compared with other local treatment modalities (*P* \< 0.001) ([Figure S2B](#S1){ref-type="supplementary-material"}).

The effect of local treatment modalities on OS was examined based on sex. In patients who underwent CDS plus RT, OS was significantly better than that of patients who were received other local treatment modalities (*P* \< 0.001 for male patients; *P* \< 0.001 for female patients) ([Figure S3A,S3B](#S1){ref-type="supplementary-material"}). The results were also significant difference in patients who were aged ≤60 years (*P* \< 0.001) and aged \>60 years (*P* \< 0.001) ([Figure S4A,S4B](#S1){ref-type="supplementary-material"}).

In addition, CDS plus RT provided the OS benefit in patients with squamous cell carcinoma (*P* \< 0.001) ([Figure S5A](#S1){ref-type="supplementary-material"}), adenocarcinoma (*P* \< 0.001) ([Figure S5B](#S1){ref-type="supplementary-material"}), grade I-II (*P* \< 0.001) ([Figure S6A](#S1){ref-type="supplementary-material"}), and grade III-IV *P* \< 0.001) metastatic EC patients. ([Figure S6B](#S1){ref-type="supplementary-material"}).

The OS rates were compared based on tumor location for patients who were underwent different local treatment modalities ([Figure S7A--S7C](#S1){ref-type="supplementary-material"}). The prognostic effect of local treatment modalities was also found in patients with tumors located in the middle thoracic esophagus (*P* \< 0.001) and lower thoracic esophagus (*P* \< 0.001). However, in patients with tumors located in the upper thoracic esophagus, local treatment modalities were not associated with OS (*P* = 0.272).

Discussion
==========

Given the limited of studies with small sample sizes investigating the effect of local treatment in metastatic EC[@b10][@b11][@b12][@b13]. In this study, we explored the prognostic value of local treatment modalities including CDS and RT in metastatic EC based on 9,125 metastatic EC patients in the SEER database and our results found that surgery plus RT could significantly improve survival in metastatic EC.

Systematic therapy is still the first-line treatment for metastatic EC. The main purpose of local treatment lies in effective control of dysphagia, pain, bleeding, and other symptoms. The potential value of surgery and RT in metastatic EC remains controversial. In a study by Schauer *et al.*, 19 patients with stage IV Barrett's adenocarcinoma received multimodality therapy including resection of the primary tumor. No significant difference was found in postoperative morbidity and mortality between metastatic EC and locally advanced EC, but the median survival was only 9 months[@b16]. Tanaka *et al.* also found that surgery did not improve survival in stage IVB EC with distant organ metastasis (*P* = 0.1291)[@b5]. Wang *et al.* included 96 patients with stage IV EC who were received palliative chemotherapy and concurrent chemoradiotherapy (CRT), of which 14 patients underwent surgery after neoadjuvant therapy and surgery had significantly better survival than those who did not[@b11]. Two related studies also showed that long-term survival could be achieved after resection of the primary tumor and metastases of stage IV EC[@b12][@b13]. In our study, 1,273 patients received surgery with or without RT, and surgery combined with RT could significantly improve survival. Thus, multimodality therapy including surgery and RT has the potential to prolong survival in metastatic EC.

Multimodality therapy is the dominant research direction in metastatic EC. Our subgroup analysis showed that in 2000--2012, patients who underwent surgery plus RT obtained a significantly better survival than patients in 1988--1999. Although the SEER data could not reflect specific conditions in patients regarding chemotherapy and targeted therapy, we speculated that it was closely correlated with of the effect of systemic treatment in metastatic EC[@b17][@b18][@b19][@b20]. Systemic therapy is the primary treatment of metastatic EC, but local treatment including surgery or RT after effective systemic therapy could further reduce the tumor burden. Therefore, we recommend for future prospective studies to investigate the effect of local treatment in metastatic EC.

Our study showed that patients with upper thoracic esophageal cancer did not benefit from local treatment, which might be related to greater difficulties in surgical treatment in upper thoracic esophageal cancer than middle and lower thoracic esophageal cancer. We could not clarify the effect of surgical treatment in upper thoracic metastatic EC, as only 30 patients underwent surgery with or without RT in this study.

In this study, the 5-year OS for preoperative RT plus CDS could reach 24.7%, while no significant difference in survival was seen for primary CDS and CDS plus postoperative RT (5-year OS, 6.5% and 7.8%, respectively), indicating that preoperative neoadjuvant therapy has a greater value in metastatic EC. Our study found that the OS improvement for surgery plus RT was mainly reflected by preoperative RT which could provide the best chance for the complete resection of primary tumors.

There are several limitations in our study. First, inherent biases exist in any retrospective study. Second, due to the limitations of SEER data, we could not obtain related information including chemotherapy, indications for surgery and RT, and range of non-regional lymph node metastases and distant metastases. In addition, patients with distant SEER stage were intended to approximate stage IV in the TNM staging system, and our results also promoted that OS of distant stage in SEER was substantially similar to that of stage IV esophageal carcinoma. Several different extent of disease schemes have been used in the SEER database. Therefore, a potential difference in the two staging systems should be considered. However, the primary strength of this study was the ability to assess the epidemiology, prognostic factors, and local treatment modalities in metastatic EC using a SEER registry. Although retrospective reviews are generally considered inferior to prospective studies, no prospective study design has been performed to assess the clinical value of local treatment in metastatic EC.

In conclusion, surgery plus RT, especially preoperative RT, may improve long-term survival of patients with metastatic EC. A prospective study on metastatic EC should be conducted to investigate the effect of local treatment in metastatic EC. Our findings may play an important role in local treatment considerations in metastatic EC if further confirmed in studies with larger sample sizes.

Methods and Materials
=====================

Patients
--------

Data were obtained from the current SEER database to identify patients with EC diagnosed in 1988--2012. We obtained permission to access research data files with the reference number 11252-Nov 2014[@b21]. Patients included in this study had the following criteria: 1) metastatic thoracic esophageal cancer with a known tumor location; and 2) local treatment modalities including cancer-directed surgery (CDS), beam radiotherapy, CDS plus RT, or no local treatment. Metastatic disease was defined as having a distant stage at diagnosis according to the SEER historic stage. Distant stage was defined as a neoplasm that had spread to parts of the body remote from the primary tumor through direct extension, discontinuous metastasis (e.g., implantation or seeding) to distant organs and tissues, or the lymphatic system to distant lymph nodes[@b21]. Patients were excluded from the analysis if they had an estimated survival of ≤3 months after diagnosis. SEER data did not require informed consent, and this study was approved by the ethics committee of the Sun Yat-sen University Cancer Center.

Clinicopathological and treatment factors
-----------------------------------------

The following clinicopathological and treatment factors were collected from the SEER database: year of diagnosis, age at diagnosis, race, tumor histology, tumor location, grade, and local treatment modalities. Vital status including cause of death and duration of follow-up was recorded.

Statistical analysis
--------------------

The χ^2^ and Fisher's exact probability tests were used to analyze differences between qualitative data. Univariate and multivariate Cox regression analyses were generated to analyze risk factors for overall survival (OS). Multivariable analyses were performed for factors that were significantly associated with OS in univariate analyses. Survival rates were calculated and plotted using the Kaplan--Meier method and compared using the log-rank test. All data were analyzed using the SPSS statistical software package, version 21.0 (IBM Corporation, Armonk, NY, USA). A *P* value of \<0.05 was considered significant.
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###### Patient characteristics.

  Characteristic        n      CDS (%)       RT (%)      CDS + RT (%)    None (%)     *P-*value
  ------------------- ------ ------------ ------------- -------------- ------------- -----------
  Year of diagnosis                                                                  
   1988--1992          514    67 (15.7)     288 (6.0)      55 (6.5)      104 (3.4)     \<0.001
   1993--1997          668    68 (16.0)     406 (8.5)      55 (6.5)      139 (4.5)         
   1998--2002          1755   111 (26.1)   898 (18.8)     204 (24.1)    542 (17.7)         
   2003--2007          2854   102 (23.9)   1489 (31.1)    258 (30.5)    1005 (32.8)        
   2008--2012          3334   78 (18.3)    1705 (35.6)    275 (32.5)    1276 (41.6)        
  Race                                                                               
   Black               1016   49 (11.5)    645 (13.5)      59 (7.0)      263 (8.6)     \<0.001
   White               7621   356 (83.6)   3832 (80.1)    750 (88.5)    2683 (87.5)        
   Other               488     21 (4.9)     309 (6.5)      38 (4.5)      120 (3.9)         
  Age                                                                                
   ≤60                 3515   159 (37.3)   1773 (37.0)    419 (49.5)    1164 (38.0)    \<0.001
   \>60                5610   267 (62.7)   3013 (63.0)    428 (50.5)    1902 (62.0)        
  Sex                                                                                
   Male                7486   349 (81.9)   3867 (80.8)    736 (86.9)    2534 (82.6)    \<0.001
   Female              1639   77 (18.1)    919 (19.2)     111 (13.1)    532 (17.4)         
  Tumor histology                                                                    
   Squamous            2757   111 (26.1)   1769 (37.0)    207 (24.4)    670 (21.9)     \<0.001
   Adenocarcinoma      5406   270 (63.4)   2574 (53.8)    543 (64.1)    2019 (65.9)        
   Other               962    45 (10.6)     443 (9.3)     97 (11.5)     377 (12.3)         
  Tumor location                                                                     
   Upper thoracic      483     8 (1.9)      340 (7.1)      27 (3.2)      108 (3.5)     \<0.001
   Middle thoracic     1647   62 (14.6)    1029 (21.5)    110 (13.0)    446 (14.5)         
   Lower thoracic      6995   356 (83.6)   3417 (71.4)    710 (83.8)    2512 (81.9)        
  Grade (n = 7653)                                                                   
   G1                  270     14 (3.6)     143 (3.6)      24 (3.2)      89 (3.5)       0.271
   G2                  2826   138 (35.8)   1522 (38.0)    287 (38.4)    879 (34.9)         
   G3-4                4557   234 (60.6)   2339 (58.4)    436 (58.4)    1548 (61.5)        

CDS, cancer-directed surgery; RT, radiotherapy; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated.

###### Univariate analysis of overall survival.

  Characteristic                 HR        95% CI      *P-*value
  ---------------------------- ------- -------------- -----------
  Year of diagnosis             0.975   0.971--0.979    \<0.001
  Age                           1.008   1.006--1.010    \<0.001
  Race                                                
   Black                          1                         
   White                        0.922   0.860--0.988     0.021
   Other                        0.89    0.793--0.998     0.047
  Sex                                                 
   Male                           1                         
   Female                       0.974   0.920--1.031     0.359
  Tumor histology                                     
   Squamous                       1                         
   Adenocarcinoma               0.977   0.931--1.026     0.347
   Other                        1.092   1.010--1.180     0.027
  Tumor location                                      
   Upper thoracic                 1                         
   Middle thoracic              1.061   0.953--1.181     0.280
   Lower thoracic               0.982   0.890--1.083     0.716
  Grade                                               
   G1                             1                         
   G2                           1.028   0.900--1.174     0.684
   G3-4                         1.179   1.035--1.344     0.013
  Local treatment modalities                          
   CDS                            1                         
   RT                           1.291   1.162--1.435    \<0.001
   CDS + RT                     0.690   0.608--0.784    \<0.001
   None                         1.384   1.242--1.542    \<0.001

CDS, cancer-directed surgery; RT, radiotherapy; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; HR, hazard ratio; CI, confidence interval.

###### Multivariate analyses of overall survival.

  Characteristic                 HR        95% CI      *P-*value
  ---------------------------- ------- -------------- -----------
  Year of diagnosis             0.971   0.967--0.975    \<0.001
  Age                           1.007   1.005--1.009    \<0.001
  Race                                                
   Black                          1                         
   White                        0.906   0.834--0.985     0.021
   Other                        0.884   0.779--1.003     0.055
  Tumor histology                                     
   Squamous                       1                         
   Adenocarcinoma               1.099   1.035--1.167     0.002
   Other                        1.174   1.072--1.286     0.001
  Grade                                               
   G1                             1                         
   G2                           1.067   0.934--0.985     0.337
   G3-4                         1.202   1.055--1.371     0.006
  Local treatment modalities                          
   CDS                            1                         
   RT                           1.440   1.287--1.611    \<0.001
   CDS + RT                     0.793   0.693--0.908     0.001
   None                         1.602   1.427--1.799    \<0.001

CDS, cancer-directed surgery; RT, radiotherapy; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; HR, hazard ratio; CI, confidence interval.
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